US 7435741
2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
granted A61PA61P3/10
Quick answer
US patent 7435741 (2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Oct 09 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Grant date
- Tue Oct 14 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 09 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 43
- CPC classes
- A61P, A61P3/10